Swiss Medica

Hier mal etwas vorweg

30-May-2007

Non-Reliance on Previous Financials, Audits or Interim Review

ITEM 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review)

On May 21, 2007, the management of Swiss Medica, Inc. (the "Company" or "Swiss Medica") concluded that its previously issued financial statements as of and for

(i) the year ended December 31, 2005, (ii) the three months ended March 31, 2006, June 30, 2006 and September 30, 2006, should no longer be relied as a result of the Company mistakenly:

(i) recording as revenues the value of certain goods sold to customers where title and risk of ownership had not passed to the customer.

(ii) accounting for the contractually re-pricing of the stated exercise price of the warrants to acquire the Company's common stock issued to the holders of the Company's debentures.

Accordingly, the Company will restate its financial statements for the year ended December 31, 2005 and for the first three quarters of 2006 by disclosing the effect of the errors in its Form 10-KSB for the year ended December 31, 2006.

The errors were discovered together with our outside independent registered accounting firm in connection with their audit of the Company's December 31, 2006 financial statements. The audit firm requested that we provided additional information concerning the recognition of our revenues in connection with the sale and delivery of our products. Upon reviewing the accounting for the transactions, we discovered our errors in recognizing revenues from certain transactions. Upon this determination, management and the Board of Directors were alerted to the facts and circumstances regarding the errors in accounting for the revenue recognition

In connection with the accounting for the re-pricing of the warrants' exercise price, the audit firm requested that we provided additional information concerning the accounting for warrant liability derivative in connection with the issuance of the warrants. Upon determining the derivative arising from the warrant liability did not take into the Warrants' exercise price was to be re-set should shares of the Company's common stock be sold below the contract exercise price , management and the Board of Directors were alerted to the facts and circumstances regarding the errors in accounting for the warrant liability.

Authorized officers of the Company discussed these matters with the Company's independent public accounting firm who agreed that the Company's annual and quarterly financial statements could not be relied upon and needed to be restated.

Gefunden auf http://biz.yahoo.com/e/070530/swmee.ob8-k.html

Hallo Zusammen

Verfolge nun diesen Titel schon einige Zeit scheint mir langsam aber sicher mal einen Blick wert.

Was haltet ihr von diesem Titel?

Ist jemand investiert?

Schöne Abe !!

Schaut euch mal diese News an:

Swiss Medica Launches New Multi-Channel Distribution Strategy

for Canada

TORONTO, July 12 /PRNewswire-FirstCall/ -- Swiss Medica, Inc. (OTC Bulletin Board: SWME) announced today it has launched a new multi-channel distribution strategy for its Canadian business segment focused on the retail, professional and private label channels.

Swiss Medica launched O24 Pain Neutralizer in Canadian national retailers in the fall of 2004 with an aggressive public relations and marketing strategy focused on 30 minute informational radio segments, in-store sampling of O24, consumer trade shows and detailing of medical professionals. O24 was well received by the Canadian marketplace and Swiss Medica's Canadian market revenues in 2005 were approximately US$1.6 million. O24 Pain Neutralizer's 1 ounce bottle was the third best selling SKU in Canada in 2005 in retailers and outsold many major brands including Ben-Gay(TM), Tiger Balm(TM) and Icy Hot(TM).

In 2006, Swiss Medica launched O24 Fibromyalgia into the Canadian retail marketplace and lowered its Canadian marketing spend to focus on its USA retail launch. In addition, it focused its lower Canadian media spend on mainstream marketing strategies including short-form radio ads and sponsorships. The combination of lower marketing dollars and ineffective mainstream media resulted in reduced O24 sales in Canada of approximately US$700,000.

Despite the reduction in sales, O24 has gained a loyal following in Canada with both consumers and the physician community who are looking for a safe and effective alternative for pain, versus both prescription and over-the-counter pills. In addition, O24 is available in most major retailers in Canada and has secured attractive shelf placement in most retailers. Swiss Medica plans to re-launch its aggressive guerilla marketing strategies (from 2005) in the fall of 2007 with long-form 30 minute radio segments with doctors on the radio talking about O24 and call in questions from the audience. In addition, O24 will be re-introduced to the physician community and an aggressive in-store sampling campaign for O24 will recommence to allow consumers to quickly recognize the superior efficacy of O24 versus other products. Swiss Medica believes that it can grow its monthly Canadian retail revenues to levels higher than 2005 within 12 months.

In addition, Swiss Medica has commenced private labelling O24 to Canadian distributors of healthcare products who are selling Swiss Medica's patented product using their own brands. Swiss Medica has completed two private label distribution deals thus far in the past year. Swiss Medica supports its private label customers with training and previously developed marketing and product science literature, but the private label customer must spend its own marketing and media dollars to support their private label brands. These and other private label deals have the potential to materially grow Swiss Medica's Canadian revenues in 2008 and provide excellent net margins as Swiss Medica is not spending dollars on consumer media to support these private label brands.

Swiss Medica is currently in discussions with several large medical product distributors who have expressed strong interest in distributing O24 to hospitals, clinics and healthcare professionals. O24's unique patented process, its strong medical and clinical trial results and its safety profile make it an ideal candidate for the Canadian healthcare professional market. Swiss Medica expects to conclude a distribution arrangement for the professional marketplace by the end of 2007.

Ben Gay is a registered trademark of Johnson & Johnson. Tiger Balm is a registered trademark of Haw Par Healthcare Ltd. Icy Hot is a trademark of Chattem, Inc.

Hallo Koebeler

Ja super vielleicht kommt nun etwas schwung in den stock...bin auch ziemlich gross long. Kaufe immer etwas dazu!

Habe mir den Investment Report vom August 2006 von del la rue intensiv angeschaut, und muss sage das alles sehr interessant ist.

Ich werde auf jeden Fall weiter zukaufen

Schönen Tag!

und er marschiert weiter!

hallo zusammen

wo wird diese aktie gehandelt? bei swissquote kann ich sie nicht finden... danke für eure hilfe

Hallo koebler

Was meinst du eckt sich da jemand ein auf die zahlen? Wer weiß vielleicht weiß da jemand mehr! Grez

:? Sorry für das koebler!!

Lange war es ruhig um die swissmedica Inc. , aber das könnte sich bald ändern.

Anleger rechneten schon mit der Insolvenz des 2005 umjubelten Biotech-Unternehmen. Die Umsätze kletterten 2004 und 2005 von Quartal zu Quartal prozentual im zwei bis dreistelligen Bereich. Von anfänglichen Ausstellungen auf kleinen regionalen Messen, schafften es die Produkte bis ins landesweite Fernsehen. Nachrichtensender berichteten über die tolle Wirksamkeit der neuen Naturheilmittel. Selbst ein eigener Werbespot wurde gedreht und ausgestrahlt. Große US-Handelsketten wie RiteAid und CVS nahmen die Produkte in ihr Sortiment.

Doch dann brach der Umsatz ein. Nach eigenen Unternehmensangaben führten falsche Absprachen mit den Handelsketten zu der Rückgabe von mehreren tausenden Produkten. Als Newcomer hatte das Unternehmen zudem kaum Cash-Reserven und sich mit hohen Marketingkosten bereits übernommen. Der große amerikanische Markt brach dem Unternehmen sprichwörtlich "das Genick".

Anfang 2007 dann ein erster Hoffnungsschimmer. Das Unternehmen erhielt eine Finanzspritze von knapp 600 TUSD. Kurz darauf wurde ein Unternehmens-Update veröffentlicht. In diesem ging hervor, dass sich während der Funkstille viel getan haben soll. Die Geschäftsstrategie wurde überarbeitet und interne Arbeitsabläufe gestrafft.

Mitte Juli wurde dann das Comeback angekündigt. Ab Hebst will das Unternehmen in Kanada erneut eine Werbeoffensive starten. Der kanadische Markt ist im Gegensatz zum amerikanischen Markt wesentlich überschaubarer und loyaler. Der amerikanische Markt erfordert schon aufgrund der Größe ein hohes Werbebudget. Zudem zählen die amerikanischen Kunden zu "unloyalen-Kunden", soll heißen, sie lassen sich leicht von anderen Werbekampagnen beeinflussen und sind einem einzelnen Produkt nur selten treu.

Die swissmedica Inc. wird sich daher auf den kanadischen Markt konzentrieren und zusätzlich Lizenzen an andere Unternehmen vergeben. Das führt zu zusätzliche Lizenz-Einnahmen, ohne hohe Werbeausgaben aufbringen zu müssen und verbessert zudem die Geschäftsstruktur.

Wir halten daher nach wie vor am Unternehmen und deren Produkten fest. Das Management hat bewiesen, auch in schwierigen Zeiten eine Lösung zu finden. Nun liegt es an der Umestzung.

Angaben zur Veröffentlichung

Datum: 04.08.2007

Uhrzeit: 11.00

Authoren: DEL LA RUE

http://www.dellarue.de/Ausgabe.html

Wer weiss vielleicht sehen wir wieder mal den double digit 8)

HAllo Koebeler

Ist doch kein Problem

Wie meinst du das mit dem das Zahlen nichts mehr sagen?

Hey Koebeler habe mich nie wegen den Prozent % genervt im Gegenteil je höher desto besser

Das mit dem double digit war auf den absoluten Wert bezogen!

TORONTO, Aug. 8 /PRNewswire-FirstCall/ -- Swiss Medica

(OTC Bulletin Board: SWME) announced today that it will launch a new

distribution strategy in the USA focused on direct-to-consumer selling and

distribution via medical professionals. In addition, Swiss Medica has decided

to strategically exit the working capital intensive USA national pharmacy

channel that caused the bulk of Swiss Medica's recent operational and

financial difficulties.

Swiss Medica launched O24 Pain Neutralizer and O24 Fibromyalgia in 2005 in

national pharmacy chains in the USA, after a similar successful launch in

Canada. Swiss Medica made a large investment in upfront inventory for the

retailers in advance of the launch, spent several millions dollars on radio

and other mainstream marketing in the USA and carried receivables from

pharmacies for six months plus in most cases. Swiss Medica's unsuccessful

experience with USA retailers were due to:

1) Mainstream short-form radio marketing that could not differentiate

O24's superior efficacy and science from its competitors.

2) An overinvestment in inventory for re-orders that did not materialize

3) Predatory supplier practices of large pharmacies who charged large fees

without approval, returned inventory that was damaged for full credit and had

extremely slow payment processes for small manufacturers. Swiss Medica

continues to pursue collections from its USA national pharmacy customers.

Swiss Medica recognized that the national pharmacy retail channel is not

the most appropriate channel in the United States for O24 whose unique patent

and clinical/medical trials need to be explained in detail in formats such as

the 1 hour branded radio shows that were successful in Canada, but are not as

available in the United States. In addition O24's efficacy can be best proven

by using a towelette sample of O24.

The USA direct-to-consumer marketplace is the most developed and elaborate

in the world, allowing manufacturers many means to bypass retailers and access

consumers directly. Swiss Medica is working to launch the distribution of O24

with a major USA-based direct-to-consumer marketing organization which focuses

on marketing products through mailing samples of products to the millions of

customers in their database and then auto-shipping regular orders of products

to customers who opt-into the re-order program. This company chose O24 after

an extensive product due diligence process and has estimated that it can build

a large regular direct order business for a private label O24 due to the

extremely high efficacy and customer satisfaction after the use of a single

compact O24 towelette. Another pain relief product distributed by the same

company experienced initial demand that translated in several million dollars

of annualized wholesale revenues to the manufacturer.

The direct-to-consumer channel is much more attractive to Swiss Medica due

to lower investments in upfront inventory, better payment terms from direct-

to-consumer marketing partners and no need to spend consumer marketing dollars

in the United States.

Hier noch die Quelle

http://biz.yahoo.com/prnews/070808/clw022.html?.v=98

auch die negativen Tagen sollte man erwähnen!! :x

ich habe schon wieder nachgekauft

=> http://biz.yahoo.com/e/070820/swme.ob10qsb.html

Sieht nicht pralle aus, aber im 2. Quartal war ja schlielich noch die Neuausrichtung.

im 3. Quartal sollten wir schon eine leichte steigerung sehen.

im 4 dann schon hoffentlich moderate zuwächse.

naja,

solange SWME nix handfestes vorweisen kann,

bleiben die breits gebeutelten Aktionäre sicherlich vorsichtig und neigen zu schnellen Gewinnmitnahmen.

Die Phantasie, muss erstmal wiederkommen,

Eine Übernahme der SWISS MEDICA Inc. durch die Amerikanische Ärztekammer steht kurz bevor (die Verträge sind bereits gezeichnet); es wird daher ein massiver Anstieg der Aktienwert prognostiziert.

Die Info findet man unter www.swissmedica.de

Rubrik " Über uns"

Hallo Zäme

Wo genau steht diese message habe sie auf der swissemedica homepage ? habe diese news nicht gefunden!

Falls das wirklich kommt uiuiuiuiuiuiuiuiuiuiuiuiuiuiI, dann muss ich koebeler ein dinner zahlen, weil du mich auf diese aktie aufmerksam gemacht hast

ah jetzt habe ich es gefunden!

Darf man soetwas in die Homepage schreiben bzw muss man die investoren darauf aufmerksam machen???

Wer ist die amerikanische Ärztekammer eigentlich?